{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:13:47Z","timestamp":1790187227562,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006544","name":"Ministry of Health, State of Israel","doi-asserted-by":"publisher","award":["3-0000-15095"],"award-info":[{"award-number":["3-0000-15095"]}],"id":[{"id":"10.13039\/501100006544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.tranon.2024.101939","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T18:34:10Z","timestamp":1710441250000},"page":"101939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells"],"prefix":"10.1016","volume":"44","author":[{"given":"Yifat Koren","family":"Carmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3330-2959","authenticated-orcid":false,"given":"Abed","family":"Agbarya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Khamaisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Farah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Shechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Korobochka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Gopas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-2039","authenticated-orcid":false,"given":"Jamal","family":"Mahajna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.tranon.2024.101939_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of ovarian cancer","volume":"9","author":"Gaona-Luviano","year":"2020","journal-title":"Chin. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2024.101939_bib0002","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.tranon.2024.101939_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2024.101939_bib0004","first-page":"35","article-title":"Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance","volume":"2","author":"Andrews","year":"1990","journal-title":"Cancer Cells"},{"key":"10.1016\/j.tranon.2024.101939_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2016.05.020","article-title":"Primary and acquired platinum-resistance among women with high grade serous ovarian cancer","author":"Slaughter","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2024.101939_bib0006","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1002\/jcp.26289","article-title":"Molecular mechanisms of drug resistance in ovarian cancer","volume":"233","author":"Norouzi-Barough","year":"2018","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.tranon.2024.101939_bib0007","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0079-6603(01)67026-0","article-title":"Cisplatin: from DNA damage to cancer chemotherapy","volume":"67","author":"Cohen","year":"2001","journal-title":"Prog. Nucl. Acid Res. Mol. Biol."},{"issue":"1","key":"10.1016\/j.tranon.2024.101939_bib0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-013-9456-2","article-title":"Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition","volume":"33","author":"Thibault","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.tranon.2024.101939_bib0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1479-5876-11-28","article-title":"Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model","volume":"11","author":"Touboul","year":"2013","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.tranon.2024.101939_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000448942","article-title":"Bevacizumab in ovarian cancer: state of the art and unanswered questions","volume":"62","author":"Musella","year":"2017","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.tranon.2024.101939_bib0011","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.hoc.2018.07.007","article-title":"Bowtell DDL. mechanisms of drug resistance in high-grade serous ovarian cancer","volume":"32","author":"Freimund","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.tranon.2024.101939_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2021.02.007","article-title":"Targeting the tumour microenvironment in platinum-resistant ovarian cancer","volume":"77","author":"Cummings","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.tranon.2024.101939_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051299","article-title":"The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer","volume":"9","author":"Nowak","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.tranon.2024.101939_bib0014","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/sj.bjc.6602495","article-title":"Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma","volume":"92","author":"Ahmed","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2024.101939_bib0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.1441","article-title":"Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid","volume":"201","author":"Ahmed","year":"2003","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.tranon.2024.101939_bib0016","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1101\/gad.1636908","article-title":"Migratory neighbors and distant invaders: tumor-associated niche cells","volume":"22","author":"Wels","year":"2008","journal-title":"Genes Dev."},{"issue":"7015","key":"10.1016\/j.tranon.2024.101939_bib0017","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature03096","article-title":"Stromal fibroblasts in cancer initiation and progression","volume":"432","author":"Bhowmick","year":"2004","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.tranon.2024.101939_bib0018","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ijc.22840","article-title":"Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K\/Akt pathway in human ovarian carcinoma cells","volume":"121","author":"Lane","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2024.101939_bib0019","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kipps","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2024.101939_bib0020","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl499","article-title":"Pattern and prognostic factors in patients with malignant ascites: a retrospective study","volume":"18","author":"Ayantunde","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2024.101939_bib0021","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"issue":"18","key":"10.1016\/j.tranon.2024.101939_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186533","article-title":"Flavonoids restore platinum drug sensitivity to ovarian carcinoma cells in a phospho-ERK1\/2-dependent fashion","volume":"21","author":"Koren Carmi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.tranon.2024.101939_bib0023","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5114\/aoms.2020.101042","article-title":"Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells","volume":"17","author":"Regev","year":"2021","journal-title":"Arch. Med. Sci."},{"issue":"9","key":"10.1016\/j.tranon.2024.101939_bib0024","doi-asserted-by":"crossref","first-page":"7730","DOI":"10.3390\/ijms24097730","article-title":"Secreted soluble factors from tumor-activated mesenchymal stromal cells confer platinum chemoresistance to ovarian cancer cells","volume":"24","author":"Koren Carmi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.tranon.2024.101939_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27030804","article-title":"2-hydroxyestradiol overcomes mesenchymal stem cells-mediated platinum chemoresistance in ovarian cancer cells in an ERK-independent fashion","volume":"27","author":"Khamaisi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.tranon.2024.101939_bib0026","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12885-016-2182-8","article-title":"Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study","volume":"16","author":"Ratzon","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2024.101939_bib0027","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s11033-012-2282-8","article-title":"Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines","volume":"40","author":"Najajreh","year":"2013","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.tranon.2024.101939_bib0028","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/1471-2407-12-411","article-title":"Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I","volume":"12","author":"Mian","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2024.101939_bib0029","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/1471-2407-12-563","article-title":"Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism","volume":"12","author":"Khateb","year":"2012","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2024.101939_bib0030","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.tranon.2024.101939_bib0031","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus","volume":"136","author":"Wenzel","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.tranon.2024.101939_bib0032","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jcph.1513","article-title":"Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib","volume":"60","author":"Mohamed","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"19 Pt 1","key":"10.1016\/j.tranon.2024.101939_bib0033","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","article-title":"Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"759","key":"10.1016\/j.tranon.2024.101939_bib0034","doi-asserted-by":"crossref","first-page":"eabj4220","DOI":"10.1126\/scisignal.abj4220","article-title":"Metabolite activation of tumorigenic signaling pathways in the tumor microenvironment","volume":"15","author":"Low","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.tranon.2024.101939_bib0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1741-7015-10-102","article-title":"Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study","volume":"10","author":"Kronenberger","year":"2012","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.tranon.2024.101939_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188639","article-title":"The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients","volume":"1876","author":"Szulc-Kielbik","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"11","key":"10.1016\/j.tranon.2024.101939_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110406","article-title":"Cancer associated fibroblasts: naughty neighbors that drive ovarian cancer progression","volume":"10","author":"Dasari","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2024.101939_bib0038","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semcancer.2019.06.003","article-title":"The multifaceted role of mesenchymal stem cells in cancer","volume":"60","author":"Timaner","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.tranon.2024.101939_bib0039","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2010.02.019","article-title":"Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells","volume":"295","author":"Wang","year":"2010","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.tranon.2024.101939_bib0040","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/1381612822666151124234417","article-title":"Interleukin-6: a critical cytokine in cancer multidrug resistance","volume":"22","author":"Ghandadi","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tranon.2024.101939_bib0041","article-title":"IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer","author":"Sun","year":"2014","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.tranon.2024.101939_bib0042","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.2174\/138161212802002797","article-title":"Interleukin-6\/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer","volume":"18","author":"Dijkgraaf","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"55","key":"10.1016\/j.tranon.2024.101939_bib0043","doi-asserted-by":"crossref","first-page":"94040","DOI":"10.18632\/oncotarget.21541","article-title":"Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice","volume":"8","author":"Reeves","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.tranon.2024.101939_bib0044","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1530\/RAF-22-0020","article-title":"Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies","volume":"3","author":"Rosario","year":"2022","journal-title":"Reprod. Fertil."},{"issue":"1","key":"10.1016\/j.tranon.2024.101939_bib0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ygyno.2012.06.009","article-title":"Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"127","author":"Schilder","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2024.101939_bib0046","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/bjc.2012.158","article-title":"Phase I study of saracatinib (AZD0530) in combination with paclitaxel and\/or carboplatin in patients with solid tumours","volume":"106","author":"Kaye","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2024.101939_bib0047","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2015.08.010","article-title":"Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum","volume":"139","author":"Nakamura","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2024.101939_bib0048","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2010.12.355","article-title":"Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis","volume":"121","author":"Aune","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2024.101939_bib0049","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","article-title":"An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms","volume":"67","author":"Zou","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2024.101939_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/genes12050742","article-title":"MET expression and cancer stem cell networks impact outcome in high-grade serous ovarian cancer","volume":"12","author":"Baath","year":"2021","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.tranon.2024.101939_bib0051","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.bbagen.2018.11.005","article-title":"Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review","volume":"1863","author":"Binju","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"4","key":"10.1016\/j.tranon.2024.101939_bib0052","first-page":"1667","article-title":"Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer","volume":"9","author":"Huang","year":"2017","journal-title":"Am. J. Transl. Res."},{"issue":"65","key":"10.1016\/j.tranon.2024.101939_bib0053","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.18632\/oncotarget.27363","article-title":"Hedenfalk I. Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer","volume":"10","author":"Sahin","year":"2019","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.tranon.2024.101939_bib0054","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0609","article-title":"Successful treatment of patients with refractory high-grade serous ovarian cancer with GOPC-ROS1 fusion using crizotinib: a case report","volume":"25","author":"Dong","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.tranon.2024.101939_bib0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.steroids.2010.02.016","article-title":"2-Methoxyestradiol\u2013biology and mechanism of action","volume":"75","author":"Mueck","year":"2010","journal-title":"Steroids"},{"key":"10.1016\/j.tranon.2024.101939_bib0056","article-title":"Combined effects of 2-methoxyestradiol (hypoxia-inducible factor 1alpha inhibitor) and dasatinib (a second-generation tyrosine kinase inhibitor) on chronic myelocytic leukemia cells","volume":"2022","author":"Zhang","year":"2022","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.tranon.2024.101939_bib0057","doi-asserted-by":"crossref","first-page":"13316","DOI":"10.1038\/s41598-019-49649-1","article-title":"Adipocytes promote ovarian cancer chemoresistance","volume":"9","author":"Yang","year":"2019","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.tranon.2024.101939_bib0058","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1177\/15353702211023846","article-title":"Adipose-derived stem cells in ovarian cancer progression, metastasis, and chemoresistance","volume":"246","author":"Zhang","year":"2021","journal-title":"Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.tranon.2024.101939_bib0059","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0262-1746(86)90084-3","article-title":"Fatty acid composition and arachidonic acid metabolites in ascitic fluid of patients with ovarian cancer","volume":"22","author":"Punnonen","year":"1986","journal-title":"Prostaglandins Leukot Med."},{"issue":"28","key":"10.1016\/j.tranon.2024.101939_bib0060","doi-asserted-by":"crossref","first-page":"26565","DOI":"10.1074\/jbc.M413056200","article-title":"Prostaglandin E2 Stimulates the beta-catenin\/T cell factor-dependent transcription in colon cancer","volume":"280","author":"Shao","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.tranon.2024.101939_bib0061","doi-asserted-by":"crossref","first-page":"14287","DOI":"10.1074\/jbc.M313276200","article-title":"Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells","volume":"279","author":"Shao","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"2 Suppl 7","key":"10.1016\/j.tranon.2024.101939_bib0062","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.seminoncol.2004.03.041","article-title":"COX-2 inhibition and colorectal cancer","volume":"31","author":"Koehne","year":"2004","journal-title":"Semin. Oncol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:28:56Z","timestamp":1761845336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523324000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":62,"alternative-id":["S1936523324000664"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2024.101939","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2024.101939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101939"}}